HomeCompareMNILY vs ABBV

MNILY vs ABBV: Dividend Comparison 2026

MNILY yields 3.16% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MNILY wins by $532.43M in total portfolio value· pulled ahead in Year 3
10 years
MNILY
MNILY
● Live price
3.16%
Share price
$16.00
Annual div
$0.50
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$532.53M
Annual income
$501,966,698.88
Full MNILY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MNILY vs ABBV

📍 MNILY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNILYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNILY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNILY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNILY
Annual income on $10K today (after 15% tax)
$268.18/yr
After 10yr DRIP, annual income (after tax)
$426,671,694.05/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MNILY beats the other by $426,650,638.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNILY + ABBV for your $10,000?

MNILY: 50%ABBV: 50%
100% ABBV50/50100% MNILY
Portfolio after 10yr
$266.32M
Annual income
$250,995,735.32/yr
Blended yield
94.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MNILY
No analyst data
Altman Z
0.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNILY buys
0
ABBV buys
0
No recent congressional trades found for MNILY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNILYABBV
Forward yield3.16%3.06%
Annual dividend / share$0.50$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$532.53M$102.3K
Annual income after 10y$501,966,698.88$24,771.77
Total dividends collected$530.28M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MNILY vs ABBV ($10,000, DRIP)

YearMNILY PortfolioMNILY Income/yrABBV PortfolioABBV Income/yrGap
1$11,331$631.01$11,550$430.00$219.00ABBV
2$13,461$1,336.45$13,472$627.96$11.00ABBV
3← crossover$17,370$2,967.54$15,906$926.08+$1.5KMNILY
4$25,744$7,157.92$19,071$1,382.55+$6.7KMNILY
5$47,375$19,829.11$23,302$2,095.81+$24.1KMNILY
6$118,898$68,206.00$29,150$3,237.93+$89.7KMNILY
7$447,176$319,955.03$37,536$5,121.41+$409.6KMNILY
8$2,727,738$2,249,259.78$50,079$8,338.38+$2.68MMNILY
9$28,564,129$25,645,449.41$69,753$14,065.80+$28.49MMNILY
10$532,530,317$501,966,698.88$102,337$24,771.77+$532.43MMNILY

MNILY vs ABBV: Complete Analysis 2026

MNILYStock

Minor International Public Company Limited, together with its subsidiaries, operates as a hospitality, restaurant, and lifestyle company in Thailand, China, Australia, and internationally. It operates in four segments: Hotel, Mixed use, Restaurant, and Retail. As of December 31, 2021, the company had approximately 2,389 restaurant outlets in 23 countries under The Pizza Company, The Coffee Club, Riverside, Benihana, Thai Express, Bonchon, Swensen's, Sizzler, Dairy Queen, and Burger King brands. It also invested in, owned, and operated a portfolio of 520 hotels and serviced suites under the Anantara, Avani, Oaks, Tivoli, NH Collection, NH Hotels, nhow, Elewana Collection, Four Seasons, St. Regis, JW Marriott, Radisson Blu, and Minor International brands in 56 countries across the Asia Pacific, the Middle East, Africa, the Indian Ocean, Europe, and the Americas. In addition, the company distributes fashion and lifestyle products under the Anello, Bodum, Bossini, Charles & Keith, Esprit, Joseph Joseph, OVS, Radley, Zwilling J.A. Henckels, and Minor Smart Kids brands through approximately 386 retail points of sale; and provides online shopping and contract manufacturing services. Further, it is involved in the shopping mall, food and beverage sale, spa, supply chain management, distribution, management, vacation club point sale, entertainment, franchise, marketing, consulting, tour operation, asset management, airport lounge, and healthcare businesses; property investment, development, and sales activities; operation of business school; and manufacture and sale of cheese and ice-cream. The company was formerly known as Royal Garden Resorts Plc. and changed its name to Minor International Public Company Limited in 2005. Minor International Public Company Limited was founded in 1978 and is headquartered in Bangkok, Thailand.

Full MNILY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MNILY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNILY vs SCHDMNILY vs JEPIMNILY vs OMNILY vs KOMNILY vs MAINMNILY vs JNJMNILY vs MRKMNILY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.